Renal Function and Antithrombin Agents in Acute Coronary Syndromes

Impaired renal function increased bleeding risk with enoxaparin, compared with fondaparinux.

Previously reported results from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) trial suggested that major bleeding events in acute coronary syndromes are less frequent in patients treated with fondaparinux than in those treated with enoxaparin (Journal Watch Cardiology Apr 6 2006). How might renal dysfunction, which increases the rate of major bleeding events in ACS, affect bleeding risks associated with these agents? In a subgroup analysis, OASIS-5 investigators studied data from 19,979 patients with non–ST-segment-elevation MI for whom baseline creatinine measures were available, stratified by quartiles of glomerular filtration rate (GFR).

Distribution of GFR was well balanced by treatment assignment. At…

Reviewing Author

Joel M. Gore, MD

Disclosures

Grant/Research SupportNIH–National Heart, Lung, and Blood Institute

Joel M. Gore, MD

Disclosures

Grant/Research SupportNIH–National Heart, Lung, and Blood Institute